InduPro’s Post

This week, our CSO, Nick Stub Laursen, will be attending the 16th International Conference on Complement Therapeutics in Loutraki, Ancient Corinth, Greece.    Nick will be delivering a poster presentation on new data from Commit Biologics innovative BiCE platform which will show that Commit’s second generation #BiCE™ molecules induce superior complement-mediated cell killing compared to other technologies.   With a novel mechanism of action, Commit’s technology has the potential to be developed into best-in-class therapeutics for the treatment of cancer and autoimmune diseases.   To read more on the presentation, read the press release in the comments below!   #ComplementSystem #ImmuneSystem #Antibodies

Sweet Basil plant's internal messengers wield a remarkable power: annihilating human cancer cells. Explore the findings in our latest publication in Wiley's Journal of Extracellular Biology. Nature's messengers, extracellular vesicles, enable plant cells to communicate. Unleashing their potential, we've harnessed these tiny powerhouses to combat cancer with significant potency. Witness the impact of sweet basil particles as they engage in cross-species combat against pancreatic cancer, showcasing unparalleled killing properties. #ISEV #JexBio #JExBio #plantscience #cancerresearch #pharmaceuticals #Pennmedicine #Upenn https://lnkd.in/esTsQpft

Your monthly dose of updates and news from Noble Life Sciences is here! 📰 🖥️ Watch Our Webinar with QIAGEN On Demand 👨🔬 Meet with Us at an Upcoming Conference 🔬 Learn About Our Oncology CRO Services Click here to read: https://ow.ly/T5oO50QGv1L #biotechindustry #pharmanews #researchanddevelopment #oncology #lifesciences #biotechnology #healthtech #research #cellandgene #invitro #assays #webinar #newsletter

When cytotoxic T cells want to kill cancer cells, they can make them self-destruct through a process called apoptosis, or programmed cell death. This happens in two ways: from outside the cell (extrinsic) or inside the cell (intrinsic). In the intrinsic pathway, a substance called granzymes is sent into the cancer cell by another protein called perforin. Once inside, granzymes cut a protein called BID, creating a shorter version of it. This shorter BID then starts a chain reaction that leads to the cancer cell destroying itself. Why is this important? By understanding and using these processes, scientists can develop treatments that specifically target and kill cancer cells. #pharma #research #biotech #medical #monitoring #qualityassurance #quality #drug 

Let's make the drug development journey faster, cheaper and more predictable. 🧪 Our team of scientists excel in combining knowledge of cancer with cutting-edge mathematics to develop sophisticated models that help speed up the complex stages of drug development, from initial pre-clinical stages to the critical clinical phases. Our approach minimises reliance on time-consuming lab work and animal studies, ensuring you get it right the first time. Ready to de-risk your drug development journey? Contact us today: https://lnkd.in/eYmCKgmX #Cancer #DrugDevelopment #VirtualTumour #Immunotherapy #CancerDrugs #CancerSimulation #CombinationTherapies #QSP #MathematicalModelling #PKPD #MechanisticModelling #Oncology #ClinicalTrials #ResearchandDevelopment #CancerResearch #BioTech #StatisticalModelling #MachineLearning #Pharma #PYC

🗣️''The number of complex antibody-based therapeutics is increasing, offering new hope for the treatment of complex diseases such as cancer and auto-immune diseases.'' ―Johanna Howson, Lead Applications Scientist, Purolite. Created with acid sensitivities of newer molecules in mind, DurA Cycle was designed to allow for a milder pH elution with less product loss; improving yields and increasing productivity in your #downstream purification processes. Find out more about DurA Cycle: https://bit.ly/3RZ8oRl

📈 Quarterly Report #Patrys has today released its Quarterly Activities Report and Appendix 4C Quarterly Cash Flow report for the quarter ended 31 March 2024.   Key highlights from this period include: 🔹 GMP production run initiated during the quarter, and successfully completed in April with product characterisation and quality verification on track for completion in Q2 CY2024; 🔹 Positive preclinical data highlights the potential to use deoxymabs to treat vasculitis, and potentially other autoimmune diseases, presented at international workshop; 🔹 Cash and short-term investment balance of $3 million on 31 March 2024.   Read today’s ASX release here 👉 https://lnkd.in/gpRr9ehc    $PAB #ASX #research #innovation #biotech #cancer #antibodies 

Explore the advanced applications of Nucleosome Quantification (Nu.Q®) technology for drug development and disease monitoring! This session features leading experts in epigenetics and assay development – Eric A. Ariazi, PhD, and Terry Kelly, PhD. Presentations will focus on the critical role of nucleosome-based markers in accelerating oncology clinical trials and enhancing drug efficacy and safety monitoring. Learn more & register here: https://bit.ly/3vLcdkX Key topics will include: ☑️ Next-generation epigenetic immunoassay for quantitative assessment of circulating nucleosomes ☑️ The role of Histone PTMs as biomarkers for chromatin-targeted therapies ☑️ Liquid biopsy applications in precision oncology ☑️ Expanding the utility of circulating nucleosomes to predict adverse reactions in therapy, including CAR-T cell treatment Thank you to Volition for making this webinar possible! #Immunoassay #Epigenetics #Genetherapy

Stay ahead in the world of cancer research! 🤩 Explore the latest findings with CLIN. Access is just a click away and completely complimentary! Details here 👉 bit.ly/3OxnaMc #CancerResearch #HealthcareNews #ClinicalTrialUpdates #Pharma #BioTech #LARVOL